Functional genomics dissects pathomechanisms in tauopathies: Mitosis failure and unfolded protein response

Neurodegenerative Diseases

Volumn 5, Issue 3-4, 2008, Pages 179-181

  Götz, Jürgen ^a   David, Della ^a   Hoerndli, Frederic ^c   Ke, Yazi D ^a   Schonrock, Nicole ^a   Wiesner, Andreas ^a   Fath, Thomas ^b   Bokhari, Laita ^a   Lim, Yun An ^a   Deters, Natasha ^a   Ittner, Lars M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Amyloid; Alzheimer's disease; Frontotemporal dementia; P301L tau; Proteomics; Transcriptomics; Transgenic mice; Valosin containing protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; MUTANT PROTEIN; TAU PROTEIN; VALOSIN CONTAINING PROTEIN;

CELL CYCLE REGULATION; CELL PROLIFERATION; CONFERENCE PAPER; ENDOPLASMIC RETICULUM STRESS; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL GENOMICS; HUMAN; MITOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEOMICS; TAUOPATHY; TRANSCRIPTOMICS; TRANSGENIC MOUSE;

ANIMALS; GENOMICS; HUMANS; MITOSIS; PROTEIN FOLDING; TAU PROTEINS; TAUOPATHIES;

EID: 40449087425     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000113696     Document Type: Conference Paper

References (10)

1. Götz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F: Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 2004;9:664-683.
2. David D, Hoerndli F, Götz J: Functional genomics meets neurodegenerative disorders. 1. Transcriptomic and proteomic technology. Prog Neurobiol 2005;76:153-168.
3. Hoerndli F, David D, Götz J: Functional genomics meets neurodegenerative disorders. 2. Transcriptomic and proteomic technology. Prog Neurobiol 2005;76:169-188.
4. Götz J, Chen F, van Dorpe J, Nitsch RM: Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science 2001;293:1491-1495.
5. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Götz J: Beta-amyloid induces PHF-like tau filaments in tissue culture. J Biol Chem 2003;278:40162-40168.
6. Hoerndli FJ, Pelech S, Papassotiropoulos A, Götz J: Abeta treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry. Eur J Neurosci 2007;26:60-72.
7. Hoerndli FJ, Toigo M, Schild A, Götz J, Day PJ: Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal Biochem 2004;335:30-41.
8. David DC, et al: Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 2005;280:23802-23814.
9. David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, Götz J: β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 2006;6:6566-6577.
10. Guinto JB, Ritson GP, Taylor JP, Forman MS: Valosin-containing protein and the pathogenesis of frontotemporal dementia associated with inclusion body myopathy. Acta Neuropathol 2007;114:55-61.